Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

High Risk Myeloma Treatment Options with Dr. Robert Orlowski

  • Broadcast in Health
  • 0 comments
CureTalks

CureTalks

×  

Follow This Show

If you liked this show, you should follow CureTalks.
h:350019
s:9803043
archived

Myeloma is classified as high-risk based on presence of cytogenetic abnormalities and poor treatment outcomes. Despite many new drugs and drug combinations being approved, long term benefits for high risk multiple myeloma patients is less clear. We continue our discussion on high risk myeloma with Dr. Robert Orlowski and talk about the treatment options that are available for a high risk patient.

Robert Z. Orlowski, MD, PhD, is Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine and medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy, with a focus on the molecular pathogenesis of oncologic disease processes and the mechanisms of action of chemotherapeutics.

Comments

 comments